MX2019011762A - Compuesto de 4-piridona o su sal, y composicion y formulacion farmaceutica que incluye el mismo. - Google Patents

Compuesto de 4-piridona o su sal, y composicion y formulacion farmaceutica que incluye el mismo.

Info

Publication number
MX2019011762A
MX2019011762A MX2019011762A MX2019011762A MX2019011762A MX 2019011762 A MX2019011762 A MX 2019011762A MX 2019011762 A MX2019011762 A MX 2019011762A MX 2019011762 A MX2019011762 A MX 2019011762A MX 2019011762 A MX2019011762 A MX 2019011762A
Authority
MX
Mexico
Prior art keywords
salt
compound
pharmaceutical composition
hepatitis
formulation including
Prior art date
Application number
MX2019011762A
Other languages
English (en)
Inventor
mashiko Tomoyuki
Ookubo Megumi
Fukunaga Hirofumi
SEKINE Shinichiro
Kawai Hyoei
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of MX2019011762A publication Critical patent/MX2019011762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

El propósito de la presente invención es proporcionar: un compuesto que tiene actividad anti-VHB o una sal del mismo; una composición farmacéutica; un agente del virus antihepatitis B; un inhibidor de la generación de ADN de un virus de hepatitis B; y un inhibidor de la generación o secreción del antígeno superficial de la hepatitis B. De acuerdo con la presente invención, se proporciona un compuesto o una sal del mismo, el compuesto que está representado por la fórmula general [1] (en la fórmula, R1 representa un grupo benzotiazolilo sustituible (aquí, los átomos de carbono que constituyen un anillo de 6 elementos del benzotiazolilo) del enlace R1 al átomo de nitrógeno de un anillo de piridina); R2 representa un grupo alquenilo de C2-6 sustituible o similar; y R3 representa un átomo de hidrógeno o similar).
MX2019011762A 2017-03-31 2018-03-30 Compuesto de 4-piridona o su sal, y composicion y formulacion farmaceutica que incluye el mismo. MX2019011762A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017069837 2017-03-31
JP2017166413 2017-08-31
PCT/JP2018/013580 WO2018181883A1 (ja) 2017-03-31 2018-03-30 ４－ピリドン化合物またはその塩、それを含む医薬組成物および剤

Publications (1)

Publication Number Publication Date
MX2019011762A true MX2019011762A (es) 2019-12-02

Family

ID=63676176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011762A MX2019011762A (es) 2017-03-31 2018-03-30 Compuesto de 4-piridona o su sal, y composicion y formulacion farmaceutica que incluye el mismo.

Country Status (15)

Country Link
US (1) US11161830B2 (es)
EP (1) EP3604301B1 (es)
JP (1) JP6813665B2 (es)
KR (1) KR20190122762A (es)
CN (1) CN110475775B (es)
AU (1) AU2018246563B2 (es)
BR (1) BR112019020401A2 (es)
CA (1) CA3058111A1 (es)
ES (1) ES2895023T3 (es)
MX (1) MX2019011762A (es)
RU (1) RU2019130519A (es)
SG (1) SG11201909094VA (es)
TW (1) TW201841911A (es)
WO (1) WO2018181883A1 (es)
ZA (1) ZA201906451B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017155844A1 (en) 2016-03-07 2017-09-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
KR102556744B1 (ko) 2017-08-28 2023-07-18 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10865211B2 (en) 2018-09-21 2020-12-15 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020106816A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2022268154A1 (zh) * 2021-06-24 2022-12-29 上海齐鲁制药研究中心有限公司 新型抗乙肝化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5980665A (ja) 1982-10-29 1984-05-10 Toyama Chem Co Ltd ４−オキソ−１，４−ジヒドロニコチン酸誘導体
DE3338846A1 (de) * 1982-10-29 1984-05-03 Toyama Chemical Co. Ltd., Tokyo Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben
GB8509086D0 (en) * 1985-04-09 1985-05-15 Fujisawa Pharmaceutical Co Dihydronicotinic acid derivatives
JPH0261947A (ja) 1988-08-26 1990-03-01 Matsushita Electric Ind Co Ltd 画像表示装置
DE3934082A1 (de) 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
US6777420B2 (en) * 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
CN1465567A (zh) 2002-06-21 2004-01-07 陈依军 二氢吡啶酮类衍生物及其用途
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
ES2826273T3 (es) 2008-09-24 2021-05-17 Melinta Subsidiary Corp Proceso para la fabricación de compuestos de quinolona
WO2010110231A1 (ja) * 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
BR112012021652A2 (pt) * 2010-03-04 2016-06-21 Merck Sharp & Dohme composto, uso do mesmo, e, composição farmacêutica
CN103992290B (zh) 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 二芳基乙烯结构类似化合物及其制备方法和应用
CN107207505B (zh) * 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
WO2017013046A1 (en) 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
JP6723254B2 (ja) * 2015-10-05 2020-07-15 富士フイルム富山化学株式会社 抗ｂ型肝炎ウイルス剤

Also Published As

Publication number Publication date
JPWO2018181883A1 (ja) 2020-01-16
KR20190122762A (ko) 2019-10-30
SG11201909094VA (en) 2019-11-28
RU2019130519A (ru) 2021-04-30
US11161830B2 (en) 2021-11-02
US20200017459A1 (en) 2020-01-16
AU2018246563A1 (en) 2019-10-17
CN110475775B (zh) 2023-05-09
WO2018181883A1 (ja) 2018-10-04
CN110475775A (zh) 2019-11-19
TW201841911A (zh) 2018-12-01
BR112019020401A2 (pt) 2020-04-22
CA3058111A1 (en) 2018-10-04
AU2018246563B2 (en) 2020-07-30
RU2019130519A3 (es) 2021-04-30
EP3604301B1 (en) 2021-09-22
EP3604301A1 (en) 2020-02-05
ZA201906451B (en) 2021-01-27
JP6813665B2 (ja) 2021-01-13
ES2895023T3 (es) 2022-02-17
EP3604301A4 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
MX2019011762A (es) Compuesto de 4-piridona o su sal, y composicion y formulacion farmaceutica que incluye el mismo.
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
MY144895A (en) Macrocylic inhibitors of hepatitis c virus
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
HRP20160863T1 (hr) Supstituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za liječenje infekcija hepatitis c virusa
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
EA200800484A1 (ru) Макроциклические ингибиторы вируса гепатита с
TW200642683A (en) Heterocyclic compound
MX344669B (es) Agente antiplaquetas novedoso.
JP2009541289A5 (es)
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
GEP20227373B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EA200400617A1 (ru) Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
AR082079A1 (es) Derivados del acido 2-naftalen-acetico, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de la proliferacion del virus hiv
HUP0401819A2 (hu) Proteinkináz inhibitorokként alkalmazható pirazolvegyületek és ezeket tartalmazó gyógyszerkészítmények
ZA200709304B (en) Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity
NZ596615A (en) Substituted isoquinoline derivative
EA200400616A1 (ru) ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
JP2017503760A5 (es)
MX2019013815A (es) Inhibidor de antigenos de superficie del virus de la hepatitis b.
PE20171433A1 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih